Comparison of low dose versus ultra-low dose hormone therapy in menopausal symptoms and quality of life in perimenopause women
Comparison of low dose versus ultra-low dose hormone therapy in menopausal symptoms and quality of life in perimenopause women
复制标题
低剂量与超低剂量激素治疗对围绝经期女性更年期症状和生活质量的比较
DOI：
10.1080/09513590.2019.1666815
复制
发表时间：
2019-09
影响因子：
2
通讯作者：
Zhou Jianhong
中科院分区：
文献类型：
--
作者：
Song Yang;Xu Wenxian;Chatooah Namratta Devi;Chen Jianfang;Huang Yizhou;Chen Peiqiong;Lan Yibing;Li Chunming;Ying Qian;Ma Linjuan;Zhou Jianhong
摘要本研究旨在比较低剂量与超低剂量激素治疗（HT）对围绝经期症状和生活质量的疗效、安全性和耐受性。绝经期门诊患者25周HT治疗的回顾性分析。132名围绝经期妇女被纳入两种治疗方案：一种是低剂量HT (LD-HT)，一种是超低剂量HT （LD-HT）。在基线、4周、13周和25周评估血清促卵泡激素、雌二醇、经阴道超声（TVUS）、36项简短健康调查（SF-36）、Kupperman指数（KI）和不良反应水平的变化。治疗25周时，LD-HT组和LD-HT组SF-36各域评分均升高，KI降低，子宫内膜厚度增加，两组间差异无统计学意义。两组在不良反应发生率上的差异可以忽略不计。低剂量和超低剂量HT均可改善围绝经期症状，从而提高生活质量，减少副作用的发生。超低剂量治疗可能在安全性和耐受性方面具有更好的优势。
Abstract The study was to compare the efficacy, safety, and tolerability of low dose versus ultra-low dose hormone therapy (HT) in the management of perimenopause symptoms and quality of life. Retrospective analysis of perimenopause patients prescribed for 25 weeks HT in the outpatient clinic of menopause. A total of 132 perimenopause women were included in two treatment regimens: one with low dose HT (LD-HT) and one with ultra-low dose HT (ULD-HT). Changes in serum levels of follicle-stimulating hormone, estradiol as well as transvaginal ultrasound (TVUS), the 36-item Short Form Health Survey (SF-36), the Kupperman Index (KI), and adverse effects were assessed at baseline, 4, 13, and 25 weeks. By the end of 25 weeks of treatment, each score of SF-36 domains for both LD-HT and ULD-HT groups were increased, the KI decreased, and the endometrial thickness increased in both groups and there was no statistical difference between two groups. Both groups have negligible differences in incidence of adverse effects. Low dose and ultra-low dose HT both can serve in improving symptoms of perimenopause, thereby offering a better quality of life with decreased incidence of side effects. Ultra-low dose treatment may have a better advantage on safety and tolerance.
登录
查看更多内容
影响因子：
4.9
作者：
J. Endrikat;T. Graeser;U. Mellinger;K. Ertan;Cornelia Holz
通讯作者：
J. Endrikat;T. Graeser;U. Mellinger;K. Ertan;Cornelia Holz
DOI：
10.11910/2227-6394.2016.04.02.12
发表时间：
2016-06
影响因子：
--
作者：
Cui-ge Yu;Shu-hong Zhao;Jian-yong Shi;Wen-zhi Wang;Jialing Chen
通讯作者：
Cui-ge Yu;Shu-hong Zhao;Jian-yong Shi;Wen-zhi Wang;Jialing Chen
影响因子：
120.7
作者：
Manson, JoAnn E.;Chlebowski, Rowan T.;Stefanick, Marcia L.;Aragaki, Aaron K.;Rossouw, Jacques E.;Prentice, Ross L.;Anderson, Garnet;Howard, Barbara V.;Thomson, Cynthia A.;LaCroix, Andrea Z.;Wactawski-Wende, Jean;Jackson, Rebecca D.;Limacher, Marian;Margolis, Karen L.;Wassertheil-Smoller, Sylvia;Beresford, Shirley A.;Cauley, Jane A.;Eaton, Charles B.;Gass, Margery;Hsia, Judith;Johnson, Karen C.;Kooperberg, Charles;Kuller, Lewis H.;Lewis, Cora E.;Liu, Simin;Martin, Lisa W.;Ockene, Judith K.;O'Sullivan, Mary Jo;Powell, Lynda H.;Simon, Michael S.;Van Horn, Linda;Vitolins, Mara Z.;Wallace, Robert B.
通讯作者：
Wallace, Robert B.
DOI：
--
发表时间：
1992
期刊：
--
影响因子：
--
作者：
Ware J.E.Jr.;C. Sherburne
通讯作者：
Ware J.E.Jr.;C. Sherburne
影响因子：
2.6
作者：
S. Malik;D. Pannu;S. Prateek;R. Sinha;Harsha S Gaikwad
通讯作者：
S. Malik;D. Pannu;S. Prateek;R. Sinha;Harsha S Gaikwad